Should I buy or sell Sonnet BioTherapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares. View SONN analyst ratings or view top-rated stocks .

What is Sonnet BioTherapeutics' stock price target for 2024?

3 brokers have issued 12-month price objectives for Sonnet BioTherapeutics' stock. Their SONN share price targets range from $147.40 to $264.00. On average, they predict the company's stock price to reach $205.70 in the next twelve months. This suggests a possible upside of 11,721.8% from the stock's current price. View analysts price targets for SONN or view top-rated stocks among Wall Street analysts .

How have SONN shares performed in 2023?

Sonnet BioTherapeutics' stock was trading at $25.30 on January 1st, 2023. Since then, SONN shares have decreased by 93.1% and is now trading at $1.74. View the best growth stocks for 2023 here .

When is Sonnet BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our SONN earnings forecast .

How were Sonnet BioTherapeutics' earnings last quarter?

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its quarterly earnings data on Monday, February, 13th. The company reported ($17.60) EPS for the quarter, topping the consensus estimate of ($24.20) by $6.60. The firm had revenue of $0.04 million for the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 1,499.44% and a negative net margin of 12,789.38%.

When did Sonnet BioTherapeutics' stock split?

Shares of Sonnet BioTherapeutics reverse split on the morning of Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Sonnet BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO) , Sorrento Therapeutics (SRNE) , Boxlight (BOXL) , T2 Biosystems (TTOO) , Biocept (BIOC) , Trevena (TRVN) , Vaxart (VXRT) , ADMA Biologics (ADMA) and Advanced Micro Devices (AMD) .

How do I buy shares of Sonnet BioTherapeutics?

Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SONN

Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis

$1.74

-0.02 (-1.14%)

(As of 12/29/2023 ET)

Compare

Today's Range: $1.69
▼
$1.80
50-Day Range: $1.15
▼
$2.06
52-Week Range: $1.08
▼
$36.96

Volume: 86,380 shs
Average Volume: 66,777 shs
Market Capitalization: $5.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $205.70

Sonnet BioTherapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 11,721.8% Upside
$205.70 Price Target
Short Interest: Healthy
3.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.80 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Sonnet BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $205.70, Sonnet BioTherapeutics has a forecasted upside of 11,721.8% from its current price of $1.74.
Amount of Analyst Coverage
Sonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.40% of the float of Sonnet BioTherapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sonnet BioTherapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sonnet BioTherapeutics has recently increased by 49.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Sonnet BioTherapeutics does not currently pay a dividend.
Dividend Growth
Sonnet BioTherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SONN.

2.7

News and Social Media Coverage

News Sentiment
Sonnet BioTherapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Sonnet BioTherapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for SONN on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.
MarketBeat Follows
3 people have added Sonnet BioTherapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Sonnet BioTherapeutics is held by insiders.
Percentage Held by Institutions
Only 36.77% of the stock of Sonnet BioTherapeutics is held by institutions.

0.0

Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

About Sonnet BioTherapeutics Stock (NASDAQ:SONN)

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

SONN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SONN Stock News Headlines

December 27, 2023 | americanbankingnews.com

BioLineRx (NASDAQ:BLRX) & Sonnet BioTherapeutics (NASDAQ:SONN) Head to Head Contrast

December 22, 2023 | msn.com

Sonnet BioTherapeutics files for $100M mixed shelf

December 31, 2023 | MarketBeat Internal (Ad)

New Year's Sale: Get MarketBeat All Access Free For 30 Days

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription

December 21, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy

December 16, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial Fortitude

December 14, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update

October 31, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview

October 26, 2023 | benzinga.com

What's Happening With Sonnet BioTherapeutics (SONN) Shares?

December 31, 2023 | Behind the Markets (Ad)

New Year's Sale: Get 12 Months of Stock Picks for $9.00

Gear up for what's happening in the stock market in 2024. Our friends at Behind the Markets are offering an opportunity that is simply too good to pass up - 12-months of their best stock ideas for just $9.00. Don't sleep on this.

October 25, 2023 | markets.businessinsider.com

Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results

October 25, 2023 | msn.com

Sonnet BioTherapeutics down 32%, prices $4.55M stock offering

October 25, 2023 | benzinga.com

Why Sonnet BioTherapeutics (SONN) Stock Is Getting Hammered

October 25, 2023 | marketwatch.com

Sonnet BioTherapeutics Shares Slide Premarket After Stock Offering

October 25, 2023 | msn.com

Why Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?

October 25, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering

October 17, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

October 17, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Aldeyra Therapeutics (ALDX)

September 20, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

September 19, 2023 | msn.com

Sonnet BioTherapeutics regains listing compliance

September 19, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

August 31, 2023 | msn.com

Sonnet BioTherapeutics launches 1-for-22 reverse stock split

August 31, 2023 | benzinga.com

Why Sonnet BioTherapeutics Stock (SONN) Is Getting Obliterated

August 31, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split

August 17, 2023 | markets.businessinsider.com

Chardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

August 16, 2023 | marketwatch.com

Sonnet BioTherapeutics Shares Rise After FDA Approves Drug Trial

August 16, 2023 | finance.yahoo.com

Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

August 14, 2023 | finanznachrichten.de

Sonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update

See More Headlines

Receive SONN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2023
Today: 12/31/2023
Next Earnings (Estimated): 2/12/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SONN
CUSIP: N/A
CIK: 1106838
Web: www.chanticleerholdings.com
Phone: 609-375-2227
Fax: 704-366-2463
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $205.70
High Stock Price Target: $264.00
Low Stock Price Target: $147.40
Potential Upside/Downside: +11,721.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,830,000.00
Net Margins: -12,789.38%
Pretax Margin: -12,741.79%
Return on Equity: -1,499.44%
Return on Assets: -223.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.86
Quick Ratio: 0.86

Sales & Book Value

Annual Sales: $150,000.00
Price / Sales: 35.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.13) per share
Price / Book: -13.38

Miscellaneous

Outstanding Shares: 3,070,000
Free Float: 3,008,000
Market Cap: $5.34 million
Optionable: Not Optionable
Beta: 0.78

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Pankaj Mohan Ph.D. (Age 58)
Founder, Chairman, CEO & President
Comp: $927k
Dr. John K. Cini Ph.D. (Age 70)
Chief Scientific Officer & Co-Founder
Comp: $602.48k
Mr. Jay Cross (Age 53)
Chief Financial Officer
Comp: $603.42k
Mr. Donald J. Griffith CPA (Age 74)
CPA, Controller & Director
Comp: $134.05k
Ms. Susan Dexter (Age 68)
Chief Technical Officer
Dr. Richard T. Kenney FACP (Age 65)
M.D., Chief Medical Officer
Mr. Manuel Dafonseca
Head of Clinical Operations

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

SONN Stock Analysis - Frequently Asked Questions

Should I buy or sell Sonnet BioTherapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SONN shares.
View SONN analyst ratings or view top-rated stocks.
What is Sonnet BioTherapeutics' stock price target for 2024?: 3 brokers have issued 12-month price objectives for Sonnet BioTherapeutics' stock. Their SONN share price targets range from $147.40 to $264.00. On average, they predict the company's stock price to reach $205.70 in the next twelve months. This suggests a possible upside of 11,721.8% from the stock's current price.
View analysts price targets for SONN or view top-rated stocks among Wall Street analysts.
How have SONN shares performed in 2023?: Sonnet BioTherapeutics' stock was trading at $25.30 on January 1st, 2023. Since then, SONN shares have decreased by 93.1% and is now trading at $1.74.
View the best growth stocks for 2023 here.
When is Sonnet BioTherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our SONN earnings forecast.

How were Sonnet BioTherapeutics' earnings last quarter?: Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) posted its quarterly earnings data on Monday, February, 13th. The company reported ($17.60) EPS for the quarter, topping the consensus estimate of ($24.20) by $6.60. The firm had revenue of $0.04 million for the quarter. Sonnet BioTherapeutics had a negative trailing twelve-month return on equity of 1,499.44% and a negative net margin of 12,789.38%.
When did Sonnet BioTherapeutics' stock split?: Shares of Sonnet BioTherapeutics reverse split on the morning of Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Sonnet BioTherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD).
How do I buy shares of Sonnet BioTherapeutics?: Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SONN) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial